Development of a small D-enantiomeric Alzheimer's amyloid-β binding peptide ligand for future in vivo imaging applications

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Funke, Susanne Aileen ^a   Bartnik, Dirk ^a   Glück, Julian Marius ^a   Piorkowska, Kasia ^b   Wiesehan, Katja ^a   Weber, Urs ^b   Gulyas, Balazs ^c   Halldin, Christer ^c   Pfeifer, Andrea ^b   Spenger, Christian ^c,d   Muhs, Andreas ^b   Willbold, Dieter ^a,e  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b EPFL   (Switzerland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Prodema Management AG   (Switzerland)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACI 80 DERIVATIVE; ACI 80 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 81; ACI 81 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 82 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 83 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 84 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 85 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 86 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 87 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 87 LYSYL FLUORESCEIN ISOTHIOCYANATE F 19; ACI 88 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 88 LYSYL FLUORESCEIN ISOTHIOCYANATE F 19; ACI 89 LYSYL FLUORESCEIN ISOTHIOCYANATE; ACI 89 LYSYL FLUORESCEIN ISOTHIOCYANATE F 19; AMYLOID BETA BINDING PEPTIDE LIGAND; AMYLOID BETA PROTEIN; CONTRAST MEDIUM; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENANTIOMER; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NEUROIMAGING; NONHUMAN; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN SYNTHESIS; SURFACE PLASMON RESONANCE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; DIAGNOSTIC IMAGING; LIGANDS; MICE; NEURITES; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEIN BINDING;

MUS MUSCULUS;

EID: 84864228672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041457     Document Type: Article

References (34)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM, (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers & Dementia 3: 186-191.
2. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
3. Braak H, Braak E, (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18: 351-357.
4. Selkoe DJ, (1991) The molecular pathology of Alzheimer's disease. Neuron 6: 487-498.
5. Duff K, (2006) Normal and abnormal tau neurobiology. Alzheimer Dis Assoc Disord 20: 202-205.
6. Dickson TC, Vickers JC, (2001) The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience 105: 99-107.
7. Vetrivel KS, Thinakaran G, (2006) Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 66: S69-73.
8. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
9. Hardy JA, Higgins GA, (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
10. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini-mental state" J Psychiatr Res 12: 189-198 A practical method for grading the cognitive state of patients for the clinician.
11. Mohs RC, Cohen L, (1988) Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 24: 627-628.
12. Ganguli M, Rodriguez E, Mulsant B, Richards S, Pandav R, et al. (2004) Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey. J Am Geriatr Soc 52: 1668-1675.
13. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, et al. (2001) Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1143-1153.
14. Visser PJ, Scheltens P, Verhey FR, (2005) Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry 76: 1348-1354.
15. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, et al. (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67: 446-452.
16. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, et al. (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30: 1026-1036.
17. Silverman DH, (2004) Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45: 594-607.
18. Nordberg A, (2007) Amyloid imaging in Alzheimer's disease. Curr Opin Neurol 20: 398-402.
19. Nordberg A, (2008) Amyloid imaging in Alzheimer's disease. Neuropsychologia 46: 1636-1641.
20. van Groen T, Kadish I, Wiesehan K, Funke SA, Willbold D, (2009) In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. ChemMedChem 4: 276-282.
21. Wiesehan K, Stohr J, Nagel-Steger L, van Groen T, Riesner D, et al. (2008) Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide. Protein Eng Des Sel 21: 241-246.
22. Wiesehan K, Willbold D, (2003) Mirror-image phage display: aiming at the mirror. Chembiochem 4: 811-815.
23. Jahan M NS, Krasikova R, Weber U, Muhs A, Spenger C, et al. (2012) Flourine-18 labeling of three novel D-Peptides by conjugation with N-succinimidyl-4-[F-18]fluorobenzoate and preliminary examination by post mortem whole hemisphere human brain autoradiography. Nucl Med Bio 39: 315-323.
24. Gulyás B SC, Beliczai Z, Gulya K, Kása P, Jahan M, et al. (2012) Distribution and binding of 18F- labelled and 125I- labelled analogues of ACI-80, a prospective molecular imaging biomarker of disease: a whole hemisphere post mortem autoradiography study in human brains obtained from Alzheimer's disease patients. Neurochem Int 60: 153-160.
25. Bartnik D, Funke SA, Andrei-Selmer LC, Bacher M, Dodel R, et al. (2010) Differently selected D-enantiomeric peptides act on different Abeta species. Rejuvenation Res 13: 202-205.
26. van Groen T, Wiesehan K, Funke SA, Kadish I, Nagel-Steger L, et al. (2008) Reduction of Alzheimer's Disease Amyloid Plaque Load in Transgenic Mice by D3, a D-Enantiomeric Peptide Identified by Mirror Image Phage Display. ChemMedChem 3: 1848-1852.
27. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG, (2006) Analyzing a kinetic titration series using affinity biosensors. Anal Biochem 349: 136-147.
28. Morton TA, Myszka DG, Chaiken IM, (1995) Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integrated rate equation, and numerical integration. Anal Biochem 227: 176-185.
29. Dewachter I, Van Dorpe J, Smeijers L, Gilis M, Kuiperi C, et al. (2000) Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J Neurosci 20: 6452-6458.
30. Abraham GN, Podell DN, (1981) Pyroglutamic acid. Non-metabolic formation, function in proteins and peptides, and characteristics of the enzymes effecting its removal. Mol Cell Biochem 38 Spec No pp. 181-190.
31. Svedberg MM, Hall H, Hellstrom-Lindahl E, Estrada S, Guan Z, et al. (2009) [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochemistry Int 54: 347-357.
32. Milton RC, Milton SC, Kent SB, (1992) Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity. Science 256: 1445-1448.
33. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, et al. (2004) A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol 165: 937-948.
34. Wei GX, Bobek LA, (2005) Human salivary mucin MUC7 12-mer-L and 12-mer-D peptides: antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, and cytotoxicity to human cells. Antimicrob Agents Chemother 49: 2336-2342.